首页 > 最新文献

Journal of Dental Anesthesia and Pain Medicine最新文献

英文 中文
Safety and efficacy of target controlled infusion administration of propofol and remifentanil for moderate sedation in non-hospital dental practice. 靶控输注异丙酚和瑞芬太尼在非医院牙科实践中用于中度镇静的安全性和有效性。
Pub Date : 2023-02-01 DOI: 10.17245/jdapm.2023.23.1.19
Douglas Lobb, Masoud MiriMoghaddam, Don Macalister, David Chrisp, Graham Shaw, Hollis Lai

Background: Fearful and anxious patients who find dental treatment intolerable without sedative and analgesic support may benefit from moderate sedation. Target controlled infusion (TCI) pumps are superior to bolus injection in maintaining low plasma and effect-site concentration variability, resulting in stable, steady-state drug concentrations. We evaluated the safety and efficacy of moderate sedation with remifentanil and propofol using TCI pumps in non-hospital dental settings.

Methods: A prospective chart review was conducted on 101 patients sedated with propofol and remifentanil using TCI pumps. The charts were completed at two oral surgeons and one general dentist's office over 6 months. Hypoxia, hypotension, bradycardia, and over-sedation were considered adverse events and were collected using Tracking and Reporting Outcomes of Procedural Sedation (TROOPS). Furthermore, patient recovery time, sedation length, drug dose, and patient satisfaction questionnaires were used to measure sedation effectiveness.

Results: Of the 101 reviewed sedation charts, 54 were of men, and 47 were of women. The mean age of the patients was 40.5 ±18.7 years, and their mean BMI was 25.6 ± 4.4. The patients did not experience hypoxia, bradycardia, and hypotension during the 4694 min of sedation. The average minimum Mean Arterial Pressure (MAP) and heartbeats were 75.1 mmHg and 60.4 bpm, respectively. 98% of patients agreed that the sedation technique met their needs in reducing their anxiety, and 99% agreed that they were satisfied with the sedation 24 hours later. The average sedation time was 46.9 ± 55.6 min, and the average recovery time was 12.4 ± 4.4 min. Remifentanil and propofol had mean initial effect-site concentration doses of 0.96 µ/ml and 1.0 ng/ml respectively. The overall total amount of drug administered was significantly higher in longer sedation procedures compared to shorter ones, while the infusion rate decreased as the procedural stimulus decreased.

Conclusion: According to the results of this study, no patients experienced adverse events during sedation, and all patients were kept at a moderate sedation level for a wide range of sedation times and differing procedures. The results showed that TCI pumps are safe and effective for administering propofol and remifentanil for moderate sedation in dentistry.

背景:害怕和焦虑的患者如果没有镇静和镇痛支持就无法接受牙科治疗,可以从适度镇静中获益。靶控输注(TCI)泵在维持低血浆和效应位点浓度变异性方面优于单丸注射,从而产生稳定的稳态药物浓度。我们评估了在非医院牙科机构使用TCI泵使用瑞芬太尼和异丙酚适度镇静的安全性和有效性。方法:对101例经TCI泵应用异丙酚和瑞芬太尼镇静的患者进行前瞻性病历回顾。这些图表是在两名口腔外科医生和一名普通牙医办公室完成的,历时6个月。缺氧、低血压、心动过缓和过度镇静被认为是不良事件,并使用程序性镇静追踪和报告结果(TROOPS)进行收集。此外,通过患者恢复时间、镇静时间、药物剂量和患者满意度问卷来衡量镇静效果。结果:101例患者中,男性54例,女性47例。患者平均年龄40.5±18.7岁,平均BMI 25.6±4.4。在4694分钟的镇静期间,患者未出现缺氧、心动过缓和低血压。平均最低平均动脉压(MAP)和心跳分别为75.1 mmHg和60.4 bpm。98%的患者认为镇静技术满足了他们减轻焦虑的需要,99%的患者认为24小时后他们对镇静感到满意。平均镇静时间为46.9±55.6 min,平均恢复时间为12.4±4.4 min。瑞芬太尼和异丙酚的平均初始效应位点浓度剂量分别为0.96µ/ml和1.0 ng/ml。在较长时间的镇静过程中,给药的总剂量明显高于较短时间的镇静过程,而随着程序刺激的减少,输液速度也随之降低。结论:根据本研究的结果,没有患者在镇静过程中发生不良事件,所有患者在大范围的镇静时间和不同的镇静过程中都保持在中等镇静水平。结果表明,TCI泵用于异丙酚和瑞芬太尼用于牙科中度镇静是安全有效的。
{"title":"Safety and efficacy of target controlled infusion administration of propofol and remifentanil for moderate sedation in non-hospital dental practice.","authors":"Douglas Lobb,&nbsp;Masoud MiriMoghaddam,&nbsp;Don Macalister,&nbsp;David Chrisp,&nbsp;Graham Shaw,&nbsp;Hollis Lai","doi":"10.17245/jdapm.2023.23.1.19","DOIUrl":"https://doi.org/10.17245/jdapm.2023.23.1.19","url":null,"abstract":"<p><strong>Background: </strong>Fearful and anxious patients who find dental treatment intolerable without sedative and analgesic support may benefit from moderate sedation. Target controlled infusion (TCI) pumps are superior to bolus injection in maintaining low plasma and effect-site concentration variability, resulting in stable, steady-state drug concentrations. We evaluated the safety and efficacy of moderate sedation with remifentanil and propofol using TCI pumps in non-hospital dental settings.</p><p><strong>Methods: </strong>A prospective chart review was conducted on 101 patients sedated with propofol and remifentanil using TCI pumps. The charts were completed at two oral surgeons and one general dentist's office over 6 months. Hypoxia, hypotension, bradycardia, and over-sedation were considered adverse events and were collected using Tracking and Reporting Outcomes of Procedural Sedation (TROOPS). Furthermore, patient recovery time, sedation length, drug dose, and patient satisfaction questionnaires were used to measure sedation effectiveness.</p><p><strong>Results: </strong>Of the 101 reviewed sedation charts, 54 were of men, and 47 were of women. The mean age of the patients was 40.5 ±18.7 years, and their mean BMI was 25.6 ± 4.4. The patients did not experience hypoxia, bradycardia, and hypotension during the 4694 min of sedation. The average minimum Mean Arterial Pressure (MAP) and heartbeats were 75.1 mmHg and 60.4 bpm, respectively. 98% of patients agreed that the sedation technique met their needs in reducing their anxiety, and 99% agreed that they were satisfied with the sedation 24 hours later. The average sedation time was 46.9 ± 55.6 min, and the average recovery time was 12.4 ± 4.4 min. Remifentanil and propofol had mean initial effect-site concentration doses of 0.96 µ/ml and 1.0 ng/ml respectively. The overall total amount of drug administered was significantly higher in longer sedation procedures compared to shorter ones, while the infusion rate decreased as the procedural stimulus decreased.</p><p><strong>Conclusion: </strong>According to the results of this study, no patients experienced adverse events during sedation, and all patients were kept at a moderate sedation level for a wide range of sedation times and differing procedures. The results showed that TCI pumps are safe and effective for administering propofol and remifentanil for moderate sedation in dentistry.</p>","PeriodicalId":15634,"journal":{"name":"Journal of Dental Anesthesia and Pain Medicine","volume":"23 1","pages":"19-28"},"PeriodicalIF":0.0,"publicationDate":"2023-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/25/3b/jdapm-23-19.PMC9911961.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10817311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Importance of Harnessing Neurophysiological Placebo Analgesic Mechanisms Through Therapeutic Contextual Factors When Treating Patients with Chronic Pain 在治疗慢性疼痛患者时,通过治疗环境因素利用神经生理安慰剂镇痛机制的重要性
Pub Date : 2023-01-31 DOI: 10.33140/japm.08.01.03
Chronic pain (CP) is a multifaceted experience that has significant effects on the patients themselves, in addition to their families, social and professional situations. Therapeutic contextual factors (TCFs) are essential components of both psychological and physical interventions, and are understood to be core variables underlying the development of the analgesic placebo effect. With the emergence of imaging studies and other high-resolution medical technology in recent years, these tools have been able to highlight key cortical regions and neuroscientific mechanisms that play a part in the placebo response. The following review dissects what makes-up TCFs. In turn, the review describes various neuroscientific mechanisms that catalyze placebo analgesic responses that are triggered due to of these TCFs. Ultimately, this paper empasizes the need to use these TCFs within clinical situations, as made evidenced through current neuroscientific research, in order to provide patients with CP with the best possible outcomes and overall quality of life
慢性疼痛(CP)是一种多方面的体验,除了对患者的家庭、社会和职业状况有显著影响外,对患者自身也有显著影响。治疗背景因素(tcf)是心理和物理干预的重要组成部分,被认为是镇痛安慰剂效应发展的核心变量。随着近年来成像研究和其他高分辨率医学技术的出现,这些工具已经能够突出在安慰剂反应中起作用的关键皮层区域和神经科学机制。下面的回顾剖析了tcf的组成。反过来,该综述描述了催化安慰剂镇痛反应的各种神经科学机制,这些反应是由这些tcf引发的。最后,本文强调需要在临床情况下使用这些tcf,通过目前的神经科学研究证明,以便为CP患者提供最好的结果和整体生活质量
{"title":"The Importance of Harnessing Neurophysiological Placebo Analgesic Mechanisms Through Therapeutic Contextual Factors When Treating Patients with Chronic Pain","authors":"","doi":"10.33140/japm.08.01.03","DOIUrl":"https://doi.org/10.33140/japm.08.01.03","url":null,"abstract":"Chronic pain (CP) is a multifaceted experience that has significant effects on the patients themselves, in addition to their families, social and professional situations. Therapeutic contextual factors (TCFs) are essential components of both psychological and physical interventions, and are understood to be core variables underlying the development of the analgesic placebo effect. With the emergence of imaging studies and other high-resolution medical technology in recent years, these tools have been able to highlight key cortical regions and neuroscientific mechanisms that play a part in the placebo response. The following review dissects what makes-up TCFs. In turn, the review describes various neuroscientific mechanisms that catalyze placebo analgesic responses that are triggered due to of these TCFs. Ultimately, this paper empasizes the need to use these TCFs within clinical situations, as made evidenced through current neuroscientific research, in order to provide patients with CP with the best possible outcomes and overall quality of life","PeriodicalId":15634,"journal":{"name":"Journal of Dental Anesthesia and Pain Medicine","volume":"64 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135396251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Herbal topical anesthetics in dentistry: an exploratory review. 牙科中的草药局部麻醉剂:探索性综述。
Pub Date : 2022-12-01 Epub Date: 2022-11-24 DOI: 10.17245/jdapm.2022.22.6.419
Sunnypriyatham Tirupathi, Dharmarajan Gopalakrishnan, Sanjeevani Deshkar

Topical anesthetics are routinely used in dental practice for various purposes. They are usually available at higher dosages and have serious potential adverse reactions, such as seizures, anaphylaxis, and acquired methemoglobinemia. To date, the scope of application of herbal plants and their extracts, which have medicinal properties, has been elaborated in the field of dentistry. The growing interest in herbal medication can be attributed to the increased safety profile of herbal agents, in contrast to synthetic preparations that have a higher risk of systemic complications. Herbal preparations can induce topical anesthesia with minimal side effects. Recently, many studies have reported the use of topical herbal preparations. The current review aimed to evaluate data from various articles comparing the capacity of herbal topical anesthetic formulations and conventional synthetic anesthetics in reducing pain perception when used as local anesthesia before dental procedures.

外用麻醉剂通常用于牙科临床的各种用途。外用麻醉剂的剂量通常较高,并有严重的潜在不良反应,如癫痫发作、过敏性休克和获得性高铁血红蛋白血症。迄今为止,具有药用特性的草本植物及其提取物在牙科领域的应用范围已得到详细阐述。人们对草药的兴趣日益浓厚,这是因为草药制剂的安全性更高,而合成制剂发生全身并发症的风险更高。草药制剂可诱导局部麻醉,且副作用极小。最近,许多研究报告了局部草药制剂的使用情况。本综述旨在评估来自不同文章的数据,比较草药局部麻醉制剂和传统合成麻醉剂在牙科手术前用作局部麻醉时降低疼痛感的能力。
{"title":"Herbal topical anesthetics in dentistry: an exploratory review.","authors":"Sunnypriyatham Tirupathi, Dharmarajan Gopalakrishnan, Sanjeevani Deshkar","doi":"10.17245/jdapm.2022.22.6.419","DOIUrl":"10.17245/jdapm.2022.22.6.419","url":null,"abstract":"<p><p>Topical anesthetics are routinely used in dental practice for various purposes. They are usually available at higher dosages and have serious potential adverse reactions, such as seizures, anaphylaxis, and acquired methemoglobinemia. To date, the scope of application of herbal plants and their extracts, which have medicinal properties, has been elaborated in the field of dentistry. The growing interest in herbal medication can be attributed to the increased safety profile of herbal agents, in contrast to synthetic preparations that have a higher risk of systemic complications. Herbal preparations can induce topical anesthesia with minimal side effects. Recently, many studies have reported the use of topical herbal preparations. The current review aimed to evaluate data from various articles comparing the capacity of herbal topical anesthetic formulations and conventional synthetic anesthetics in reducing pain perception when used as local anesthesia before dental procedures.</p>","PeriodicalId":15634,"journal":{"name":"Journal of Dental Anesthesia and Pain Medicine","volume":"22 6","pages":"419-426"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cd/40/jdapm-22-419.PMC9763823.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10490033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety of hydroxyzine in the sedation of pediatric dental patients. 羟嗪在儿童牙科患者镇静中的安全性。
Pub Date : 2022-12-01 Epub Date: 2022-11-24 DOI: 10.17245/jdapm.2022.22.6.395
Taegyeom Kim, Keoungah Kim, Seungoh Kim, Jongbin Kim

Hydroxyzine is one of the most popular oral sedatives used in pediatric dentistry. This study aimed to investigate the safety and possible side effects of sedation using hydroxyzine in pediatric dentistry. "Hydroxyzine," "Dental sedation," "Child," and "Safety" and their associated synonyms were searched using the Cochrane Library, Embase, PubMed, KISS, KMBASE, and KoreaMed databases. Academic information and portals of DBpia and RISS were also perused. Altogether, 340 papers were found, among which a total of 24 papers were selected according to the detailed criteria. Nine studies used hydroxyzine as monotherapy, and 10 studies compared its safety when hydroxyzine used as multitherapy. In addition, seven studies employed a drug regimen wherein hydroxyzine was one of the components. All these studies revealed that the adverse events specific to hydroxyzine usage were drowsiness and dryness of the mouth, and that there were respiratory complications due to a synergistic reaction of hydroxyzine. Although classified as a histamine blocker, hydroxyzine with its sedative, antiemetic, anticonvulsant, and anticholinergic properties is an oral sedative available without serious adverse events, If the proper dosage of the drug is used and its synergistic effects with other drugs are ascertained in the route of administration.

羟嗪是儿童牙科最常用的口服镇静剂之一。本研究旨在调查在儿童牙科中使用羟嗪镇静的安全性和可能的副作用。研究人员使用 Cochrane Library、Embase、PubMed、KISS、KMBASE 和 KoreaMed 数据库检索了 "羟嗪"、"牙科镇静"、"儿童 "和 "安全 "及其相关同义词。此外,还浏览了 DBpia 和 RISS 的学术信息和门户网站。总共找到了 340 篇论文,其中根据详细标准选出了 24 篇论文。9 项研究使用羟嗪作为单一疗法,10 项研究比较了羟嗪作为多种疗法时的安全性。此外,有 7 项研究采用了以羟嗪为成分之一的药物疗法。所有这些研究都表明,使用羟嗪所特有的不良反应是嗜睡和口干,而且由于羟嗪的协同反应,还出现了呼吸系统并发症。尽管羟嗪被归类为组胺受体阻滞剂,但它具有镇静、止吐、抗惊厥和抗胆碱能的特性,是一种口服镇静剂,如果使用剂量适当,并在给药途径中确定其与其他药物的协同作用,则不会出现严重的不良反应。
{"title":"Safety of hydroxyzine in the sedation of pediatric dental patients.","authors":"Taegyeom Kim, Keoungah Kim, Seungoh Kim, Jongbin Kim","doi":"10.17245/jdapm.2022.22.6.395","DOIUrl":"10.17245/jdapm.2022.22.6.395","url":null,"abstract":"<p><p>Hydroxyzine is one of the most popular oral sedatives used in pediatric dentistry. This study aimed to investigate the safety and possible side effects of sedation using hydroxyzine in pediatric dentistry. \"Hydroxyzine,\" \"Dental sedation,\" \"Child,\" and \"Safety\" and their associated synonyms were searched using the Cochrane Library, Embase, PubMed, KISS, KMBASE, and KoreaMed databases. Academic information and portals of DBpia and RISS were also perused. Altogether, 340 papers were found, among which a total of 24 papers were selected according to the detailed criteria. Nine studies used hydroxyzine as monotherapy, and 10 studies compared its safety when hydroxyzine used as multitherapy. In addition, seven studies employed a drug regimen wherein hydroxyzine was one of the components. All these studies revealed that the adverse events specific to hydroxyzine usage were drowsiness and dryness of the mouth, and that there were respiratory complications due to a synergistic reaction of hydroxyzine. Although classified as a histamine blocker, hydroxyzine with its sedative, antiemetic, anticonvulsant, and anticholinergic properties is an oral sedative available without serious adverse events, If the proper dosage of the drug is used and its synergistic effects with other drugs are ascertained in the route of administration.</p>","PeriodicalId":15634,"journal":{"name":"Journal of Dental Anesthesia and Pain Medicine","volume":"22 6","pages":"395-404"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/82/f0/jdapm-22-395.PMC9763820.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10490029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anesthetic management for emergency tracheostomy in patients with head and neck cancer: a case series. 头颈癌患者急诊气管切开术的麻醉管理:一个病例系列。
Pub Date : 2022-12-01 DOI: 10.17245/jdapm.2022.22.6.457
Ci Young Kim, Seongji Cho, Seung-Hwa Ryoo

Tracheostomy is a surgical procedure that is commonly used to treat upper airway obstruction. In particular, patients with head and neck cancer may require elective or emergency tracheostomy because of airway obstruction due to massive bleeding of the intraoral tumor mass and rapid growth of the tumor mass in the neck area. Here, we report four cases of tracheostomy in patients with head and neck cancer with narrowed airway space and difficulty in breathing. Based on these cases and a literature review, we recommend that oral and maxillofacial surgeons and dental anesthesiologists should cooperate closely and determine the appropriate timing to perform definitive airway management for such patients during palliative treatment, along with continuous evaluation of tumor location, risk of recurrence, and airway involvement.

气管切开术是一种常用于治疗上气道阻塞的外科手术。特别是头颈癌患者,由于口内肿瘤肿块大量出血和颈部肿瘤肿块快速生长导致气道阻塞,可能需要择期或急诊气管切开术。在此,我们报告四例气管切开术治疗头颈癌患者气道狭窄和呼吸困难。基于这些病例和文献回顾,我们建议口腔颌面外科医生和牙科麻醉师应密切合作,并确定在姑息治疗期间对此类患者进行最终气道管理的适当时机,同时持续评估肿瘤位置、复发风险和气道受损伤。
{"title":"Anesthetic management for emergency tracheostomy in patients with head and neck cancer: a case series.","authors":"Ci Young Kim,&nbsp;Seongji Cho,&nbsp;Seung-Hwa Ryoo","doi":"10.17245/jdapm.2022.22.6.457","DOIUrl":"https://doi.org/10.17245/jdapm.2022.22.6.457","url":null,"abstract":"<p><p>Tracheostomy is a surgical procedure that is commonly used to treat upper airway obstruction. In particular, patients with head and neck cancer may require elective or emergency tracheostomy because of airway obstruction due to massive bleeding of the intraoral tumor mass and rapid growth of the tumor mass in the neck area. Here, we report four cases of tracheostomy in patients with head and neck cancer with narrowed airway space and difficulty in breathing. Based on these cases and a literature review, we recommend that oral and maxillofacial surgeons and dental anesthesiologists should cooperate closely and determine the appropriate timing to perform definitive airway management for such patients during palliative treatment, along with continuous evaluation of tumor location, risk of recurrence, and airway involvement.</p>","PeriodicalId":15634,"journal":{"name":"Journal of Dental Anesthesia and Pain Medicine","volume":"22 6","pages":"457-464"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/1f/94/jdapm-22-457.PMC9763818.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10481010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Pre-emptive analgesia efficacy of piroxicam versus tramadol in oral surgery. 吡罗昔康与曲马多在口腔手术中的预先镇痛疗效对比。
Pub Date : 2022-12-01 Epub Date: 2022-11-24 DOI: 10.17245/jdapm.2022.22.6.443
Tejdeep Muthuluri, Siddardha Gowtam Chandrupatla, Ritesh Rajan, Viveka V Reddy, Dinesh K Jhawar, Abhinand Potturi

Background: This double-blind randomized controlled trial (RCT) was conducted to evaluate the pre-emptive analgesia and anti-inflammatory efficacy of piroxicam compared with tramadol in patients undergoing oral surgery.

Methods: Seventy-eight patients who required extraction of impacted mandibular third molars were randomized into three treatment groups of 26 patients each: group I received 100 mg of tramadol, group II received 20 mg of piroxicam, and group III received a placebo. Drugs were administered intramuscularly 30 min prior to the extraction procedure.

Results: Pain intensity, time to first analgesic administration, total analgesic consumption, facial edema, and trismus were the outcomes of interest. The group receiving 20 mg of piroxicam showed significantly lower pain intensity, increased time to first analgesic, and reduced edema from preoperative to postoperative day seven than those in the tramadol and placebo groups.

Conclusion: The findings of this study showed that piroxicam had significant pain relief efficacy after third molar surgery compared with that in tramadol.

背景:这项双盲随机对照试验(RCT)旨在评估吡罗昔康与曲马多对口腔手术患者的预先镇痛和消炎疗效:78名需要拔除下颌第三磨牙的患者被随机分为三个治疗组,每组26人:第一组接受100毫克曲马多,第二组接受20毫克吡罗昔康,第三组接受安慰剂。拔牙前 30 分钟肌肉注射药物:结果:疼痛强度、首次给药时间、总镇痛剂用量、面部水肿和肢体瘫痪是研究的重点。与曲马多组和安慰剂组相比,接受 20 毫克吡罗昔康治疗的患者从术前到术后第七天的疼痛强度明显降低,首次镇痛时间明显延长,水肿明显减轻:本研究结果表明,与曲马多相比,吡罗昔康在第三磨牙手术后具有明显的止痛效果。
{"title":"Pre-emptive analgesia efficacy of piroxicam versus tramadol in oral surgery.","authors":"Tejdeep Muthuluri, Siddardha Gowtam Chandrupatla, Ritesh Rajan, Viveka V Reddy, Dinesh K Jhawar, Abhinand Potturi","doi":"10.17245/jdapm.2022.22.6.443","DOIUrl":"10.17245/jdapm.2022.22.6.443","url":null,"abstract":"<p><strong>Background: </strong>This double-blind randomized controlled trial (RCT) was conducted to evaluate the pre-emptive analgesia and anti-inflammatory efficacy of piroxicam compared with tramadol in patients undergoing oral surgery.</p><p><strong>Methods: </strong>Seventy-eight patients who required extraction of impacted mandibular third molars were randomized into three treatment groups of 26 patients each: group I received 100 mg of tramadol, group II received 20 mg of piroxicam, and group III received a placebo. Drugs were administered intramuscularly 30 min prior to the extraction procedure.</p><p><strong>Results: </strong>Pain intensity, time to first analgesic administration, total analgesic consumption, facial edema, and trismus were the outcomes of interest. The group receiving 20 mg of piroxicam showed significantly lower pain intensity, increased time to first analgesic, and reduced edema from preoperative to postoperative day seven than those in the tramadol and placebo groups.</p><p><strong>Conclusion: </strong>The findings of this study showed that piroxicam had significant pain relief efficacy after third molar surgery compared with that in tramadol.</p>","PeriodicalId":15634,"journal":{"name":"Journal of Dental Anesthesia and Pain Medicine","volume":"22 6","pages":"443-450"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0c/32/jdapm-22-443.PMC9763819.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10490032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transcutaneous electrical nerve stimulation for pain during propofol injection: a randomized clinical trial. 经皮神经电刺激治疗异丙酚注射期间疼痛:一项随机临床试验。
Pub Date : 2022-12-01 DOI: 10.17245/jdapm.2022.22.6.437
Dongwoo Lee, Juhwa Jin, Ji Hyo Kim, Jinyoung Oh, Younghoon Jeon

Background: Propofol is a short-acting intravenous sedative widely used for procedural sedation and general anesthesia. However, pain during propofol injection is a distressing adverse effect. This study was designed to investigate whether transcutaneous electrical nerve stimulation (TENS) could reduce pain during propofol injection compared to sham TENS.

Methods: In a randomized controlled trial, 80 patients were allocated to two groups: the active TENS group received electrical stimulation via two electrodes on the venous cannulation site, whereas the sham TENS group received no stimulus. After 20 min following TENS, propofol 0.5 mg/kg pain was injected intravenously and pain was evaluated using a four-point score (0 = none, 1 = mild, 2 = moderate, 3 = severe). Adverse effects associated with TENS were also recorded.

Results: The overall incidence of pain during propofol injection was 47.5% in the TENS group and 87.5% in the sham group (P < 0.001). The incidence of moderate pain was significantly lower in the TENS group (7.5%) than in the sham TENS group (42.5%) (P < 0.001). There were no complications associated with TENS.

Conclusion: Pre-treatment with TENS significantly reduced the incidence and intensity of pain during propofol injection.

背景:异丙酚是一种短效静脉镇静剂,广泛用于手术镇静和全身麻醉。然而,注射异丙酚时的疼痛是一种令人痛苦的不良反应。本研究旨在探讨经皮神经电刺激(TENS)是否能减轻异丙酚注射时的疼痛。方法:采用随机对照试验方法,将80例患者分为两组:活性TENS组在静脉插管部位通过两个电极进行电刺激,假TENS组不进行电刺激。TENS后20分钟,静脉注射异丙酚0.5 mg/kg疼痛,用4分评分(0 =无,1 =轻度,2 =中度,3 =重度)评估疼痛。还记录了与TENS相关的不良反应。结果:假手术组和TENS组在异丙酚注射过程中疼痛总发生率分别为87.5%和47.5% (P < 0.001)。中重度疼痛发生率,TENS组(7.5%)明显低于假手术组(42.5%),差异有统计学意义(P < 0.001)。TENS无并发症。结论:经TENS预处理可显著降低异丙酚注射过程中疼痛的发生率和强度。
{"title":"Transcutaneous electrical nerve stimulation for pain during propofol injection: a randomized clinical trial.","authors":"Dongwoo Lee,&nbsp;Juhwa Jin,&nbsp;Ji Hyo Kim,&nbsp;Jinyoung Oh,&nbsp;Younghoon Jeon","doi":"10.17245/jdapm.2022.22.6.437","DOIUrl":"https://doi.org/10.17245/jdapm.2022.22.6.437","url":null,"abstract":"<p><strong>Background: </strong>Propofol is a short-acting intravenous sedative widely used for procedural sedation and general anesthesia. However, pain during propofol injection is a distressing adverse effect. This study was designed to investigate whether transcutaneous electrical nerve stimulation (TENS) could reduce pain during propofol injection compared to sham TENS.</p><p><strong>Methods: </strong>In a randomized controlled trial, 80 patients were allocated to two groups: the active TENS group received electrical stimulation via two electrodes on the venous cannulation site, whereas the sham TENS group received no stimulus. After 20 min following TENS, propofol 0.5 mg/kg pain was injected intravenously and pain was evaluated using a four-point score (0 = none, 1 = mild, 2 = moderate, 3 = severe). Adverse effects associated with TENS were also recorded.</p><p><strong>Results: </strong>The overall incidence of pain during propofol injection was 47.5% in the TENS group and 87.5% in the sham group (P < 0.001). The incidence of moderate pain was significantly lower in the TENS group (7.5%) than in the sham TENS group (42.5%) (P < 0.001). There were no complications associated with TENS.</p><p><strong>Conclusion: </strong>Pre-treatment with TENS significantly reduced the incidence and intensity of pain during propofol injection.</p>","PeriodicalId":15634,"journal":{"name":"Journal of Dental Anesthesia and Pain Medicine","volume":"22 6","pages":"437-442"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bf/02/jdapm-22-437.PMC9763824.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10490030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Effectiveness of hyaluronic acid in the management of oral lichen planus: a systematic review and meta-analysis. 透明质酸治疗口腔扁平苔藓的效果:系统综述和荟萃分析。
Pub Date : 2022-12-01 Epub Date: 2022-11-24 DOI: 10.17245/jdapm.2022.22.6.405
Manjushri Waingade, Raghavendra S Medikeri, Shamali Gaikwad

Oral lichen planus (OLP) is a chronic inflammatory immune-mediated condition that has been identified as a potentially malignant oral disorder. Various therapies have been proposed for its management as alternative to corticosteroids. However, no definitive treatment has been identified that can result in complete remission or minimal recurrence. Hyaluronic acid has recently been used as an alternative therapy for the management of OLP. This study aimed to systematically review the effectiveness of Hyaluronic acid in the management of symptomatic OLP. Online electronic databases and manual searches were performed for randomized controlled trials (RCTs) published in English between January 2010 and April 2022. RCTs were identified that compared the efficacy of hyaluronic acid and other interventional therapies at baseline and during follow-up. The Cochrane Risk of Bias tool was used to assess the quality of the included studies. Visual analog scale (VAS) scores, Thongprasom sign scores, lesion size, degree of erythema, clinical severity, and disease severity were assessed both quantitatively and qualitatively. Seven studies were analyzed. Five studies reported a high risk of bias while the remaining two studies reported an unclear risk of bias. The overall quantitative assessment of size, symptoms, degree of erythema, and sign score in OLP lesions treated with HA was not statistically significant compared to that in the control group (P > 0.05). In addition, subgroup analysis comparing HA with placebo or corticosteroids did not yield statistically significant (P > 0.05) results. Qualitatively, both HA and tacrolimus resulted in an effective reduction in signs and symptoms. Clinical/disease severity index/scores were inconsistent. A high degree of heterogeneity was observed among the included studies. None of the included studies reported the side effects of HA. These findings suggest that corticosteroids, tacrolimus, placebo, and HA could be equally effective in OLP management. The clinical/disease severity index or score reduction cannot be determined with certainty. Thus, OLP can be treated with HA as an alternative therapy. Owing to limited clinical trials on HA, high heterogeneity, and high risk of bias in the included studies, definitive conclusions cannot be derived.

口腔扁平苔藓(OLP)是一种由免疫介导的慢性炎症,已被确定为一种潜在的恶性口腔疾病。人们提出了各种治疗方法,以替代皮质类固醇激素。然而,目前还没有找到一种能使病情完全缓解或复发率降至最低的确切疗法。最近,透明质酸被用作治疗 OLP 的替代疗法。本研究旨在系统回顾透明质酸在治疗有症状的OLP方面的有效性。研究人员通过在线电子数据库和人工检索,查找了2010年1月至2022年4月期间用英语发表的随机对照试验(RCT)。结果发现,这些研究比较了透明质酸和其他介入疗法在基线和随访期间的疗效。科克伦偏倚风险工具用于评估纳入研究的质量。对视觉模拟量表(VAS)评分、Thongprasom体征评分、皮损大小、红斑程度、临床严重程度和疾病严重程度进行了定量和定性评估。共分析了七项研究。其中五项研究的偏倚风险较高,其余两项研究的偏倚风险不明确。与对照组相比,用HA治疗的OLP病变的大小、症状、红斑程度和体征评分的总体定量评估没有统计学意义(P > 0.05)。此外,HA与安慰剂或皮质类固醇的亚组分析结果也没有统计学意义(P > 0.05)。从质量上看,HA 和他克莫司都能有效减轻体征和症状。临床/疾病严重程度指数/评分不一致。所纳入的研究之间存在高度异质性。所纳入的研究均未报告 HA 的副作用。这些研究结果表明,皮质类固醇、他克莫司、安慰剂和HA对治疗OLP同样有效。临床/疾病严重程度指数或评分的降低无法确定。因此,HA 可作为治疗 OLP 的替代疗法。由于有关HA的临床试验有限、异质性高以及所纳入研究的偏倚风险高,因此无法得出明确的结论。
{"title":"Effectiveness of hyaluronic acid in the management of oral lichen planus: a systematic review and meta-analysis.","authors":"Manjushri Waingade, Raghavendra S Medikeri, Shamali Gaikwad","doi":"10.17245/jdapm.2022.22.6.405","DOIUrl":"10.17245/jdapm.2022.22.6.405","url":null,"abstract":"<p><p>Oral lichen planus (OLP) is a chronic inflammatory immune-mediated condition that has been identified as a potentially malignant oral disorder. Various therapies have been proposed for its management as alternative to corticosteroids. However, no definitive treatment has been identified that can result in complete remission or minimal recurrence. Hyaluronic acid has recently been used as an alternative therapy for the management of OLP. This study aimed to systematically review the effectiveness of Hyaluronic acid in the management of symptomatic OLP. Online electronic databases and manual searches were performed for randomized controlled trials (RCTs) published in English between January 2010 and April 2022. RCTs were identified that compared the efficacy of hyaluronic acid and other interventional therapies at baseline and during follow-up. The Cochrane Risk of Bias tool was used to assess the quality of the included studies. Visual analog scale (VAS) scores, Thongprasom sign scores, lesion size, degree of erythema, clinical severity, and disease severity were assessed both quantitatively and qualitatively. Seven studies were analyzed. Five studies reported a high risk of bias while the remaining two studies reported an unclear risk of bias. The overall quantitative assessment of size, symptoms, degree of erythema, and sign score in OLP lesions treated with HA was not statistically significant compared to that in the control group (P > 0.05). In addition, subgroup analysis comparing HA with placebo or corticosteroids did not yield statistically significant (P > 0.05) results. Qualitatively, both HA and tacrolimus resulted in an effective reduction in signs and symptoms. Clinical/disease severity index/scores were inconsistent. A high degree of heterogeneity was observed among the included studies. None of the included studies reported the side effects of HA. These findings suggest that corticosteroids, tacrolimus, placebo, and HA could be equally effective in OLP management. The clinical/disease severity index or score reduction cannot be determined with certainty. Thus, OLP can be treated with HA as an alternative therapy. Owing to limited clinical trials on HA, high heterogeneity, and high risk of bias in the included studies, definitive conclusions cannot be derived.</p>","PeriodicalId":15634,"journal":{"name":"Journal of Dental Anesthesia and Pain Medicine","volume":"22 6","pages":"405-417"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a0/52/jdapm-22-405.PMC9763825.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10481009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Usefulness of lateral cephalometric radiography for successful blind nasal intubation: a prospective study. 侧位头颅x线摄影对成功的盲鼻插管的有用性:一项前瞻性研究。
Pub Date : 2022-12-01 DOI: 10.17245/jdapm.2022.22.6.427
Kana Ito, Ayaka Kamura, Kyotaro Koshika, Toshiyuki Handa, Nobuyuki Matsuura, Tatsuya Ichinohe

Background: This study aimed to investigate the relationship between pharyngeal morphology and the success or failure of blind nasotracheal intubation using standard lateral cephalometric radiography and to analyze the measurement items affecting the difficulty of blind nasotracheal intubation.

Methods: Assuming a line perpendicular to the Frankfort horizontal (FH) plane, the reference point (O) was selected 1 cm above the posterior-most end of the hard palate. A line passing through the reference point and parallel to the FH plane is defined as the X-axis, and a line passing through the reference point and perpendicular to the X-axis is defined as the Y-axis. The shortest length between the tip of the uvula and posterior pharyngeal wall (AW), shortest length between the base of the tongue and posterior pharyngeal wall (BW), and width of the glottis (CW) were measured. The midpoints of the lines representing each width are defined as points A, B, and C, and the X and Y coordinates of each point are obtained (AX, BX, CX, AY, BY, and CY). For each measurement, a t-test was performed to compare the tracheal intubation success and failure groups. A binomial logistic regression analysis was performed using clinically relevant items.

Results: The items significantly affecting the success rate of blind nasotracheal intubation included the difference in X coordinates at points A and C (Odds ratio, 0.714; P-value, 0.024) and the ∠ABC (Odds ratio, 1.178; P-value, 0.016).

Conclusion: Using binomial logistic regression analysis, we observed statistically significant differences in AX-CX and ∠ABC between the success group and the failure group.

背景:本研究旨在探讨标准侧位头位x线片咽部形态与盲鼻气管插管成功或失败的关系,并分析影响盲鼻气管插管难度的测量项目。方法:假设一条垂直于法兰克福水平平面(FH)的直线,参考点(O)选在硬腭最后端上方1cm处。通过参考点并平行于跳频平面的直线定义为x轴,通过参考点并垂直于x轴的直线定义为y轴。测量小舌尖至咽后壁的最短长度(AW)、舌根至咽后壁的最短长度(BW)和声门宽度(CW)。将代表每个宽度的线的中点定义为A、B、C点,得到每个点的X、Y坐标(AX、BX、CX、AY、BY、CY)。对于每项测量,进行t检验来比较气管插管成功组和失败组。采用临床相关项目进行二项logistic回归分析。结果:显著影响盲法鼻气管插管成功率的项目包括A、C点X坐标的差异(优势比,0.714;p值,0.024)和∠ABC(优势比,1.178;假定值,0.016)。结论:采用二项logistic回归分析,成功组与失败组之间AX-CX、∠ABC值差异有统计学意义。
{"title":"Usefulness of lateral cephalometric radiography for successful blind nasal intubation: a prospective study.","authors":"Kana Ito,&nbsp;Ayaka Kamura,&nbsp;Kyotaro Koshika,&nbsp;Toshiyuki Handa,&nbsp;Nobuyuki Matsuura,&nbsp;Tatsuya Ichinohe","doi":"10.17245/jdapm.2022.22.6.427","DOIUrl":"https://doi.org/10.17245/jdapm.2022.22.6.427","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to investigate the relationship between pharyngeal morphology and the success or failure of blind nasotracheal intubation using standard lateral cephalometric radiography and to analyze the measurement items affecting the difficulty of blind nasotracheal intubation.</p><p><strong>Methods: </strong>Assuming a line perpendicular to the Frankfort horizontal (FH) plane, the reference point (O) was selected 1 cm above the posterior-most end of the hard palate. A line passing through the reference point and parallel to the FH plane is defined as the X-axis, and a line passing through the reference point and perpendicular to the X-axis is defined as the Y-axis. The shortest length between the tip of the uvula and posterior pharyngeal wall (AW), shortest length between the base of the tongue and posterior pharyngeal wall (BW), and width of the glottis (CW) were measured. The midpoints of the lines representing each width are defined as points A, B, and C, and the X and Y coordinates of each point are obtained (AX, BX, CX, AY, BY, and CY). For each measurement, a t-test was performed to compare the tracheal intubation success and failure groups. A binomial logistic regression analysis was performed using clinically relevant items.</p><p><strong>Results: </strong>The items significantly affecting the success rate of blind nasotracheal intubation included the difference in X coordinates at points A and C (Odds ratio, 0.714; P-value, 0.024) and the ∠ABC (Odds ratio, 1.178; P-value, 0.016).</p><p><strong>Conclusion: </strong>Using binomial logistic regression analysis, we observed statistically significant differences in AX-CX and ∠ABC between the success group and the failure group.</p>","PeriodicalId":15634,"journal":{"name":"Journal of Dental Anesthesia and Pain Medicine","volume":"22 6","pages":"427-435"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b1/f6/jdapm-22-427.PMC9763822.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10481008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anesthetic management for dental surgery in a child with glycogen storage disease type IIIa: a case report. IIIa型糖原储存病患儿牙科手术的麻醉处理1例报告。
Pub Date : 2022-12-01 DOI: 10.17245/jdapm.2022.22.6.451
Buğra Aykenar, Nedim Çekmen

Glycogen storage disease (GSD) is a group of inherited disorders, which result in the deficiency of enzymes involved in glycogen metabolism, leading to an accumulation of glycogen in various organs. Deficiency of amylo-1-6-glicosidase (debranching enzyme) causes glycogen storage disease type III (GSD III). The main problems that anesthesiologists face in patients with GSD III include hypoglycemia, muscle weakness, delayed awakening due to abnormal liver function, possible difficulty in airway, and cardiomyopathy. In the face of these difficulties, airway preparation and appropriate glucose monitoring and support during the fasting period are important. The doses of the drugs to be used should be calculated considering the increased volume of distribution and decreased metabolic activity of the liver. We present the case of a child with GSD IIIa who underwent dental prosedation under general anesthesia. She was also being prepared for liver transplantation. This case was additionally complicated by the patient's serious allergic reaction to eggs and milk.

糖原储存病(GSD)是一组遗传性疾病,其主要原因是参与糖原代谢的酶缺乏,导致糖原在各器官积累。淀粉-1-6-葡糖苷酶(去分支酶)缺乏导致III型糖原贮积病(GSD III)。GSD III患者麻醉医师面临的主要问题包括低血糖、肌肉无力、肝功能异常导致的延迟苏醒、可能出现的气道困难和心肌病。面对这些困难,在禁食期间气道准备和适当的葡萄糖监测和支持是重要的。药物的剂量应考虑到分布体积的增加和肝脏代谢活性的降低。我们提出的情况下,儿童与GSD IIIa谁在全身麻醉下进行牙齿处理。她还在为肝移植做准备。该病例还伴有对鸡蛋和牛奶的严重过敏反应。
{"title":"Anesthetic management for dental surgery in a child with glycogen storage disease type IIIa: a case report.","authors":"Buğra Aykenar,&nbsp;Nedim Çekmen","doi":"10.17245/jdapm.2022.22.6.451","DOIUrl":"https://doi.org/10.17245/jdapm.2022.22.6.451","url":null,"abstract":"<p><p>Glycogen storage disease (GSD) is a group of inherited disorders, which result in the deficiency of enzymes involved in glycogen metabolism, leading to an accumulation of glycogen in various organs. Deficiency of amylo-1-6-glicosidase (debranching enzyme) causes glycogen storage disease type III (GSD III). The main problems that anesthesiologists face in patients with GSD III include hypoglycemia, muscle weakness, delayed awakening due to abnormal liver function, possible difficulty in airway, and cardiomyopathy. In the face of these difficulties, airway preparation and appropriate glucose monitoring and support during the fasting period are important. The doses of the drugs to be used should be calculated considering the increased volume of distribution and decreased metabolic activity of the liver. We present the case of a child with GSD IIIa who underwent dental prosedation under general anesthesia. She was also being prepared for liver transplantation. This case was additionally complicated by the patient's serious allergic reaction to eggs and milk.</p>","PeriodicalId":15634,"journal":{"name":"Journal of Dental Anesthesia and Pain Medicine","volume":"22 6","pages":"451-455"},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/68/38/jdapm-22-451.PMC9763821.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10490028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Dental Anesthesia and Pain Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1